Research & IP · United States

Perspective Therapeutics

Formerly IsoRay (Cs-131 brachytherapy seeds), it now develops lead-212 alpha radioligand therapies with in-house Pb-212 generator technology.

Headquarters
Seattle, United States · North America
Value chain
Research & IP(Research & design)
What that means
Invents and licenses: corporate and contract research, IP and technology licensing, with little production of its own.
Founded
1998
Ownership
Listed
Listing
NYSE American:CATX on Google Finance
Website
perspectivetherapeutics.com
Relevance
Low at its strongest, in Nuclear Medicine & Radioisotope Technologies

In 1 capability

Each capability the company is listed in, most relevant first: how experts in the field see its global relevance there, why it is listed and the source.

  1. Biotechnology & Health Technologies · Design · listed #40 of 50

    Formerly IsoRay (Cs-131 brachytherapy seeds), it now develops lead-212 alpha radioligand therapies with in-house Pb-212 generator technology.

    Relevance: Lead-212 therapy developer, early stage

    Source · perspectivetherapeutics.com